TG THERAPEUTICS, INC.

Pharmaceutical Preparations·NEW YORK, NY·FY end 12/31·CIK 1001316

CEO Pay Ratio

67:1

CEO Total Comp

—

Median Employee

$306,004

Revenue

$616.3M

FY 2025

Net Income

$447.2M

FY 2025

Free Cash Flow

-$25.0M

FY 2025

Net Margin

72.6%

Insider Net (180d)

-$162.8K

0 buys / 1 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$616.3M	$329.0M	$233.7M	$2.8M	$6.7M
Gross Profit	—	—	—	—	—	—
Operating Income	$123.3M	$41.9M	$20.6M	-$192.8M	-$344.8M
Net Income	$447.2M	$23.4M	$12.7M	—	—
Operating CF	-$24.8M	-$40.5M	-$31.4M	-$176.2M	-$295.6M
Capex	$214.0K	$45.0K	$0	$14.0K	$401.0K
Free Cash Flow	-$25.0M	-$40.6M	-$31.4M	-$176.2M	-$296.0M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	20.0%	12.7%	8.8%	-6924.2%	-5154.3%
Net Margin	72.6%	7.1%	5.4%	—	—
FCF Margin	-4.1%	-12.3%	-13.4%	-6326.2%	-4425.7%
R&D / Revenue	26.0%	28.7%	32.6%	4501.0%	3327.5%
Effective Tax	-316.4%	8.6%	3.0%	0.0%	0.0%
Debt / Equity	0.38	1.10	1.25	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Sean A. PowerChief Financial Officer, Treasurer	$500.0K	—	$2.9M	—	$327.5K	$21.0K
Michael S. WeissChief Executive	$875.0K	—	$23.6M	—	$1.1M	—